Completion rate and safety of non-invasive brain stimulation for upper limb dysfunction after stroke: a systematic review and network meta-analysis - Report - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Evaluation of Treatment Completion and Safety Profiles of Non-Invasive Brain Stimulation for Upper Limb Impairment Post-Stroke: A Systematic Review and Network Meta-Analysis
Clinical Report: Evaluation of Treatment Completion and Safety Profiles of NIBS
Overview
This systematic review and network meta-analysis assessed completion rates and safety profiles of non-invasive brain stimulation (NIBS) for upper limb rehabilitation post-stroke.
Background
Stroke is a leading cause of long-term disability, affecting millions globally. Upper limb motor dysfunction is prevalent among stroke survivors, significantly impacting their quality of life and daily activities. Non-invasive brain stimulation (NIBS) has emerged as a potential adjunctive treatment to enhance motor recovery, yet systematic evaluations of its completion rates and safety profiles are limited.
Data Highlights
Intervention
Completion Rate
Adverse Event Rate
Overall NIBS
94.9% (95% CI: 93.3–96.4%)
16.4% (95% CI: 8.5–26.2%)
tDCS
96.8%
-
rTMS
93.9%
-
Chronic Phase
97.1%
-
Mixed Phase
89.1%
-
Key Findings
The pooled completion rate for NIBS interventions was 94.9%.
Completion rates were higher for tDCS (96.8%) compared to rTMS (93.9%).
The chronic phase of stroke had the highest completion rate (97.1%).
The overall adverse event rate was 16.4%, with mild headaches and skin tingling being the most common.
Only 1.1% of participants discontinued treatment due to adverse events.
The high completion rates and favorable safety profiles of NIBS suggest its viability as an adjunctive treatment in upper limb rehabilitation post-stroke. Clinicians should consider stroke phase when designing adherence strategies for NIBS interventions.
Conclusion
NIBS demonstrates a high completion rate and acceptable safety profile for upper limb rehabilitation in post-stroke patients.
Baptist Health will bring together leading physicians, researchers and healthcare professionals from South Florida and across the country for the 14th Annual Baptist Health Miami Neuroscience Symposium, taking place Nov. 4-6, 2026, at Hilton Miami Dadeland and virtually via Zoom.